Cited by

• Acute headache management in emergency department. A narrative review.

  Giamberardino MA, Affaitati G, Costantini R, Guglielmetti M, Martelletti P. Giamberardino MA, et al. Intern Emerg Med. 2020 Jan;15(1):109-117. doi: 10.1007/s11739-019-02266-2. Epub 2020 Jan 1. Intern Emerg Med. 2020. PMID: 31893348 Review.
• The appropriate dosing of erenumab for migraine prevention after multiple preventive treatment failures: a critical appraisal.

  Ornello R, Tiseo C, Frattale I, Perrotta G, Marini C, Pistoia F, Sacco S. Ornello R, et al. J Headache Pain. 2019 Oct 30;20(1):99. doi: 10.1186/s10194-019-1054-4. J Headache Pain. 2019. PMID: 31666008 Free PMC article. Review.
• Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy.

  Ornello R, Casalena A, Frattale I, Gabriele A, Affaitati G, Giamberardino MA, Assetta M, Maddestra M, Marzoli F, Viola S, Cerone D, Marini C, Pistoia F, Sacco S. Ornello R, et al. J Headache Pain. 2020 Apr 7;21(1):32. doi: 10.1186/s10194-020-01102-9. J Headache Pain. 2020. PMID: 32264820 Free PMC article.
• Erenumab in Chronic Migraine Patients Who Previously Failed Five First-Line Oral Prophylactics and OnabotulinumtoxinA: A Dual-Center Retrospective Observational Study.

  Raffaelli B, Kalantzis R, Mecklenburg J, Overeem LH, Neeb L, Gendolla A, Reuter U. Raffaelli B, et al. Front Neurol. 2020 May 28;11:417. doi: 10.3389/fneur.2020.00417. eCollection 2020. Front Neurol. 2020. PMID: 32547474 Free PMC article.
• Erenumab and Possible CGRP Effect on Chronotype in Chronic Migraine: A Real-Life Study of 12 Months Treatment.

  Pilati L, Torrente A, Di Marco S, Ferlisi S, Notaro G, Romano M, Alonge P, Vassallo L, Ferraù L, Autunno M, Grugno R, Camarda C, Brighina F. Pilati L, et al. J Clin Med. 2023 May 21;12(10):3585. doi: 10.3390/jcm12103585. J Clin Med. 2023. PMID: 37240692 Free PMC article.